5-Amino-1MQ is an oral, small-molecule NNMT inhibitor (nicotinamide N-methyltransferase inhibitor) that has been researched for fat loss and metabolic health. It is not a true peptide and not a hormone; it is an experimental research-stage compound. Its fat-loss and metabolic effects come almost entirely from laboratory and animal studies, and published human clinical evidence is currently limited. At Menscape Clinic in Bangkok, our physicians can discuss what the current research does and does not show for men weighing their options around body composition and metabolic support.
/)
Medically reviewed by Dr. Tuksaorn Suriyakan (Ping), Anti-Aging & Regenerative Medicine Physician
8 years of experience
Our solutions for Weight-Loss Management
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
5-Amino-1MQ (5-amino-1-methylquinolinium) is an oral, small-molecule compound that inhibits an enzyme called NNMT, or nicotinamide N-methyltransferase. It is often grouped with research peptides commercially, but chemically it is a quinolinium small molecule rather than a chain of amino acids. It is taken by mouth (non-injectable), which distinguishes it from most injectable research peptides. It is an experimental compound: there is no FDA-approved 5-Amino-1MQ product, and the evidence around it is largely preclinical. Most of what is known comes from cell cultures and rodent studies rather than human trials.
/)
NNMT is an enzyme that is especially active in fat tissue. It attaches a methyl group to nicotinamide, a form of vitamin B3, which uses up cellular methyl donors and diverts nicotinamide away from the pathway that recycles it into NAD+. Researchers hypothesise that by inhibiting NNMT, more nicotinamide stays available for NAD+ production and fat-cell metabolism shifts toward higher energy expenditure. In laboratory and animal studies this has been associated with reduced fat accumulation and better glucose handling. These are proposed mechanisms drawn from preclinical work, not established human outcomes, and animal findings frequently do not replicate in people.
/)
Interest typically comes from men focused on body composition and metabolic health who have already addressed nutrition, training, sleep and stress and are curious about emerging research compounds. Because the human evidence base is so limited, it is not appropriate for everyone, and it is not a first-line approach. At Menscape Clinic in Bangkok, our physicians prioritise established, evidence-backed options first. Any conversation about an experimental compound like 5-Amino-1MQ starts with a full medical review, your goals and your risk tolerance, and an honest account of how thin the human data currently is.
/)
At Menscape Clinic in Bangkok, 5-Amino-1MQ is never a walk-in purchase. It begins with a physician consultation, a health history and, where relevant, baseline bloodwork. Because it is experimental with limited human safety data, our doctors will explain what is and is not known, discuss safer evidence-based alternatives for weight and metabolic health, and only consider it under ongoing medical supervision where clinically appropriate and legally permitted. Our English-speaking team supports local and medical-tourism patients with clear follow-up rather than a one-off transaction.
/)
Every 5-Amino-1MQ protocol starts with a full medical consultation and history review.
Prescriptions are filled by a licensed compounding pharmacy partner, not over-the-counter.
Follow-up consultations every four to six weeks to assess response and safety.
We frame 5-Amino-1MQ as a research-stage option and prescribe only when clinically appropriate.
No. 5-Amino-1MQ has no FDA-approved indication and no Investigational New Drug application or completed clinical trial on the public record. It is widely sold as a research-use-only compound rather than an approved medicine. Its legal and availability status varies by country, so any use should be discussed with a licensed physician who can advise on what is permitted in your jurisdiction.
Not really. It is often marketed alongside peptides, but chemically it is a small-molecule quinolinium NNMT inhibitor, not a chain of amino acids. One practical difference is that it is taken orally rather than injected like most research peptides.
Published human evidence is currently limited to essentially none. The fat-loss and metabolic findings come from cell cultures and rodent studies, where NNMT inhibition reduced fat mass and improved glucose tolerance. No peer-reviewed human efficacy trial has been published, so its effects in people remain unproven.
Human safety data are limited because no completed human safety trials have been published. Preclinical studies have not flagged prominent adverse effects, but absence of data is not the same as proof of safety. Because the human safety floor is genuinely uncertain, it should only ever be considered after a medical review and under physician supervision, never self-sourced from unverified vendors.
It is an oral, non-injectable compound, typically taken by mouth. Any protocol, dose or cycle should be set and monitored by a physician on an individual basis, as there is no standardised, clinically validated human dosing.
Any discussion of an experimental compound like 5-Amino-1MQ starts with a physician consultation, not a purchase. Our doctors will review your health, explain that the human evidence is limited, present established evidence-based alternatives for weight and metabolic goals, and only consider it under medical supervision where clinically appropriate and legally permitted.
/)
Dr. Tuksaorn (Dr. Ping) is an anti-aging and regenerative medicine physician with over 8 years of experience, focused on evidence-based wellness and personalized health programs that combine modern medical science with individualized care.
/)
/)
/)
/)
/)